Integrated use of telemedicine and AI in wound treatment - contributing to public sector financial and environmental sustainability and resilience during pandemics.

在伤口治疗中综合使用远程医疗和人工智能——有助于公共部门在流行病期间的财务和环境可持续性和复原力。

• 批准号: 81147
• 金额: $ 6.51万
• 依托单位: WILLINGSFORD LIMITED
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=81147
• 关键词: Integrated; use; telemedicine; AI; wound

Cost of healthcare in the UK and world-wide continues to place an increasing burden on public finances, e.g. the 2019 NHS budget was £134 billion. There are annually 2.3 million wounds in the UK, but treatment times are long and 39% remain unhealed because existing treatments are ineffective. Wounds therefore annually cost the NHS £17.3 bn and require 278 million dressing changes; this translates into 12.9% of the entire NHS budget, 51,711 full-time nurses and 20,000 tonnes of medical waste of plastics, silicones, antimicrobials and chemicals without gaining any substantial health benefits. Furthermore, wounds result in personal costs to patients, social care costs and lost productivity. Amicapsil is an easy-to-use novel wound treatment with proven efficacy. Amicapsil and its use do not involve harmful plastics, silicones chemicals or antimicrobials. The past 2 years Willingsford has supported healthcare-professionals and private patients in the use of Amicapsil. This has gradually developed into a telemedicine approach. The project will focus on developing a telemedicine approach based on the Amicapsil that can be scaled to cover the UK and later to export. Calculations indicate that this could provide annual savings in the order of £12 billion in wound care, free up at least 40,000 nurses for other tasks, improve patients' lives and reduce costs for social care. A telemedicine approach would also provide resilience during pandemics. Furthermore, Amicapsil and its use do not involve any harmful chemicals, plastics, silicones or antimicrobials, and, with telemedicine, the need for transport would be greatly reduced. The approach would contribute strongly to the net-zero UK policy and environmental protection. The platform would also be suitable for export, creating UK jobs and tax revenues. The project will initially focus on diabetic foot ulcers (DFUs) as diabetics are particularly at risk due to Covid-19 and only 16% of infected DFUs heal within the first 12 months. In 2017, there were 174,000 DFUs in the UK costing £1.37 billion; globally there are annually over 30 million DFUs.

英国和世界各地的医疗成本继续给公共财政带来越来越大的负担，例如2019年NHS预算为1340亿GB。英国每年有230万个伤口，但治疗时间很长，39%的伤口仍未愈合，因为现有的治疗方法无效。因此，每年的创伤费用为173亿英镑，需要2.78亿英镑的敷料更换；这相当于整个国民保健系统预算的12.9%，51711名全职护士和20,000吨塑料、有机硅、抗菌剂和化学品的医疗废物，却没有获得任何实质性的健康益处。此外，创伤还会导致患者的个人成本、社会护理成本和生产力损失。Amicapsil是一种简单易用的新型伤口治疗方法，已被证明有效。Amicapsil及其使用不涉及有害塑料、有机硅化学品或抗菌剂。在过去的两年里，Willingsford一直在支持医疗保健专业人员和私人患者使用Amicapsil。这已经逐渐发展成为一种远程医疗方法。该项目将专注于开发一种基于Amicapsil的远程医疗方法，该方法可以扩展到覆盖英国，然后出口。计算表明，这可以每年节省约120亿GB的伤口护理费用，解放至少40,000名护士从事其他任务，改善患者的生活，并降低社会护理成本。远程医疗方法还将在大流行期间提供韧性。此外，阿米卡西勒及其使用不涉及任何有害化学品、塑料、硅酮或抗菌剂，而且有了远程医疗，运输需求将大大减少。这种做法将对英国的净零政策和环境保护做出重大贡献。该平台还将适用于出口，为英国创造就业机会和税收。该项目最初将专注于糖尿病足部溃疡(DFU)，因为糖尿病患者因新冠肺炎而面临特别高的风险，而且只有16%的受感染的DFU在前12个月内痊愈。2017年，英国有17.4万个DFU，成本13.7亿GB；全球每年有超过3000万个DFU。